Suppr超能文献

关于天然类黄酮对 COVID-19 引起的肺部损伤的新观点。

New perspectives on natural flavonoids on COVID-19-induced lung injuries.

机构信息

Department of Bioscience, Federal University of São Paulo, Santos, São Paulo, Brazil.

Department of Immunology, Institute of Biomedical Sciences, University of São Paulo, São Paulo, São Paulo, Brazil.

出版信息

Phytother Res. 2021 Sep;35(9):4988-5006. doi: 10.1002/ptr.7131. Epub 2021 Apr 29.

Abstract

The SARS-CoV-2 virus, responsible for COVID-19, spread rapidly worldwide and became a pandemic in 2020. In some patients, the virus remains in the respiratory tract, causing pneumonia, respiratory failure, acute respiratory distress syndrome (ARDS), and sepsis, leading to death. Natural flavonoids (aglycone and glycosides) possess broad biological activities encompassing antiinflammatory, antiviral, antitumoral, antiallergic, antiplatelet, and antioxidant effects. While many studies have focused on the effects of natural flavonoids in experimental models, reports based on clinical trials are still insufficient. In this review, we highlight the effects of flavonoids in controlling pulmonary diseases, particularly the acute respiratory distress syndrome, a consequence of COVID-19, and their potential use in coronavirus-related diseases. Furthermore, we also focus on establishing a relationship between biological potential and chemical aspects of related flavonoids and discuss several possible mechanisms of action, pointing out some possible effects on COVID-19.

摘要

导致 COVID-19 的 SARS-CoV-2 病毒在全球范围内迅速传播,并于 2020 年成为大流行。在一些患者中,病毒仍存在于呼吸道中,导致肺炎、呼吸衰竭、急性呼吸窘迫综合征 (ARDS) 和败血症,导致死亡。天然类黄酮(苷元和糖苷)具有广泛的生物活性,包括抗炎、抗病毒、抗肿瘤、抗过敏、抗血小板和抗氧化作用。虽然许多研究都集中在天然类黄酮在实验模型中的作用上,但基于临床试验的报告仍然不足。在这篇综述中,我们强调了类黄酮在控制肺部疾病(特别是 COVID-19 引起的急性呼吸窘迫综合征)方面的作用,以及它们在冠状病毒相关疾病中的潜在用途。此外,我们还重点研究了相关类黄酮的生物学潜力和化学方面之间的关系,并讨论了几种可能的作用机制,指出了对 COVID-19 的一些可能影响。

相似文献

9
Viral Respiratory Pathogens and Lung Injury.病毒呼吸道病原体与肺损伤
Clin Microbiol Rev. 2021 Mar 31;34(3). doi: 10.1128/CMR.00103-20. Print 2021 Jun 16.

引用本文的文献

10
Research and development of Chinese anti-COVID-19 drugs.中国抗新冠病毒药物的研发
Acta Pharm Sin B. 2022 Dec;12(12):4271-4286. doi: 10.1016/j.apsb.2022.09.002. Epub 2022 Sep 13.

本文引用的文献

8

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验